1. Home
  2. USNA vs GLSI Comparison

USNA vs GLSI Comparison

Compare USNA & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo USANA Health Sciences Inc.

USNA

USANA Health Sciences Inc.

HOLD

Current Price

$18.81

Market Cap

342.7M

Sector

Health Care

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$27.81

Market Cap

327.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USNA
GLSI
Founded
1992
2006
Country
United States
United States
Employees
1570
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
342.7M
327.2M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
USNA
GLSI
Price
$18.81
$27.81
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$50.00
AVG Volume (30 Days)
97.1K
100.3K
Earning Date
05-05-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.41
N/A
Revenue
$1,060,902,000.00
N/A
Revenue This Year
$3.90
N/A
Revenue Next Year
$6.21
N/A
P/E Ratio
$45.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.60
$7.78
52 Week High
$38.32
$34.10

Technical Indicators

Market Signals
Indicator
USNA
GLSI
Relative Strength Index (RSI) 52.56 60.93
Support Level $16.77 $20.86
Resistance Level $21.16 $29.89
Average True Range (ATR) 0.94 1.66
MACD -0.01 0.44
Stochastic Oscillator 45.54 82.70

Price Performance

Historical Comparison
USNA
GLSI

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: